Clinical Study to Evaluate the Efficacy of Two Dentifrices for Dentine Hypersensitivity

NCT ID: NCT02371616

Last Updated: 2018-04-04

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

304 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-29

Study Completion Date

2014-12-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An 8 week clinical study to evaluate the ability of an experimental dentifrice containing calcium sodium phosphosilicate and sodium fluoride to provide relief from dentine hypersensitivity compared to a marketed dentifrice containing calcium sodium phosphosilicate and sodium monofluorophosphate.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A single centre, multi-site, randomised, examiner blind, two treatment, parallel group, non-inferiority design clinical study conducted in healthy subjects with self-reported and clinically diagnosed dentine hypersensitivity (DH). This study will compare the effectiveness of a test dentifrice containing 5% w/w calcium sodium phosphosilicate and fluoride as sodium fluoride to a commercially available dentifrice containing 5% w/w calcium sodium phosphosilicate and fluoride as sodium monofluorophosphate, in providing relief from DH after 4 and 8 weeks twice daily treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dentine Sensitivity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test dentifrice

Test dentifrice containing 5% w/w calcium sodium phosphosilicate and 1426 ppm fluoride as sodium flouride

Group Type EXPERIMENTAL

Calcium sodium phosphosilicate

Intervention Type DEVICE

5% w/w calcium sodium phosphosilicate

Sodium fluoride

Intervention Type OTHER

1426 ppm fluoride as sodium fluoride

Comparator dentifrice

Comparator dentifrice containing 5% w/w calcium sodium phosphosilicate and 1426 ppm fluoride as sodium monofluorophosphate

Group Type ACTIVE_COMPARATOR

Calcium sodium phosphosilicate

Intervention Type DEVICE

5% w/w calcium sodium phosphosilicate

Sodium monofluorophosphate

Intervention Type OTHER

1426 ppm fluoride as sodium monofluorophosphate

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Calcium sodium phosphosilicate

5% w/w calcium sodium phosphosilicate

Intervention Type DEVICE

Sodium fluoride

1426 ppm fluoride as sodium fluoride

Intervention Type OTHER

Sodium monofluorophosphate

1426 ppm fluoride as sodium monofluorophosphate

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* subjects in good general health with no clinically significant/ relevant abnormalities of oral examination
* pre-existing self reported and clinically diagnosed tooth sensitivity
* at screening a minimum of 20 natural teeth and at least two accessible, non-adjacent teeth (incisors, canines or pre-molars) with signs of erosion or abrasion and/or facial/cervical gingival recession (EAR), with a Gingival Index ≤1 and clinical mobility ≤1, and with signs of DH as measured by qualifying evaporative (air) assessment
* at baseline, a minimum of 2 non-adjacent accessible teeth (incisors, canines or premolars) with DH (qualifying tactile threshold Yeaple ≤ 20g, Schiff Sensitivity Score ≥ 2)

Exclusion Criteria

* subjects with a known or suspected intolerance or hypersensitivity to study products
* presence of chronic debilitating disease which could affect study outcomes
* any condition which is causing dry mouth
* use of an oral care product indicated for the relief of dentine hypersensitivity
* participation in a DH treatment study in the 8 weeks prior to screening
* taking daily doses of a medication/ treatment which could interfere with perception of pain or is causing dry mouth
* require antibiotic prophylaxis for dental procedures
* dental prophylaxis within 4 weeks of screening
* treatment of periodontal disease within 12 months of screening+C60
* scaling or root planing within 3 months of screening
* tooth bleaching within 8 weeks of screening
* active caries or periodontitis
* partial dentures, orthodontic appliances or dental implants which could affect study outcomes
* Pregnant and breast-feeding females
* Main Exclusions for Test Teeth: evidence of current or recent caries; treatment of decay within 12 months of screening; teeth with exposed dentine but with deep, defective or facial restorations; teeth used as abutments for fixed or removable partial dentures; teeth with full crowns or veneers, orthodontic bands or cracked enamel; sensitive teeth with contributing aetiologies other than erosion, abrasion or recession
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

Ellesmere Port, Cheshire, United Kingdom

Site Status

GSK Investigational Site

Maldon, Essex, United Kingdom

Site Status

GSK Investigational Site

Metropolitan Borough of Wirral, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

202199

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Dentinal Hypersensitivity Reduction
NCT06244290 COMPLETED PHASE3